• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nightingale Health

0.94 EUR-2.09 %21.8. klo 18.29
4,758 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.09 %
+9.35 %
+4.70 %
-41.28 %
-54.34 %
-57.45 %
+16.42 %
-82.14 %
-81.83 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
57.04M EUR
Turnover
62.07K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.06.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
The home test apparently utilized by Supernormal was, from a consumer’s perspective, a quite functional and convenient service that I would still be willing to pay for today. During the pilot phase, I was able to conduct several home tests between 2021 and 2022. Now, a few years ...
8/18/2026, 9:18 AM
by Yariskuski
18
After a long break, news is always nice, and naturally, a positive reaction in the stock price warms the heart. There are no indications of the deal size in the announcement, and PHC seems to be quite a small player, so hopefully, this is just the beginning and more announcements...
8/17/2026, 8:53 AM
by Spwni
16
Boy, there are a lot of press releases coming out now… US Healthcare Business Executive Hugh Watson Appointed as Chief Commercial Officer for Americas at Nightingale Health - Inderes Changes in the Management Team of Nightingale Health Plc - Inderes
8/19/2026, 6:31 AM
by Tuuukka
15
This is a reasonably positive sign, as Boston Heart Diagnostics is already a strategic partner of Nightingale, meaning someone is switching sides to a small Finnish company.
8/19/2026, 6:49 AM
by NukkeNukuttaja
14
Inderes Nightingale Healthin Remote Health Check osaksi Supernormalin lääkkeellistä... Nightingale Health Oyj | Lehdistötiedote | 18.08.2026 klo 09:57:00 EESTNightingale Health ja Supernormal ovat solmineet kumppanuuden, jonka myötä Nightingale Healthin Remote Health Check tulee....
8/18/2026, 7:02 AM
by Pertti
14
Inderes – 19 Aug 26 Nightingalen etätestit osaksi Supernormalin painonhallintapalvelua - Inderes Yli 10 000 jäsenen Supernormal-yhteistyö vie etätestit osaksi GLP-1-lääkehoitoja.
8/19/2026, 4:13 AM
by Pertti
10
Inderes – 18 Aug 26 Nightingalelle uusi kumppanuus Isossa-Britanniassa - Inderes Kumppanuus avaa latua Ison-Britannian yksityisen terveydenhuollon markkinalla.
8/18/2026, 4:23 AM
by Pertti
9
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 12.06.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.9.
2026

Annual report '26

5.11.
2026

General meeting '26

9.3.
2027

Interim report Q2'27

Regulatory press release19.08.2026 klo 09.00

Changes in Nightingale Health Plc's management team

Nightingale Health
Press release19.08.2026 klo 09.00

US healthcare commercial leader Hugh Watson joins Nightingale Health as Chief Commercial Officer, Americas

Nightingale Health
Nightingale's remote tests to be included in Supernormal's weight loss service
Analyst Comment19.08.2026 klo 10.12 by
Antti Siltanen

Nightingale's remote tests to be included in Supernormal's weight loss service

The Supernormal collaboration, with over 10,000 users, integrates remote testing into GLP-1 medication treatments.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release18.08.2026 klo 09.57

Nightingale Health and Supernormal partner to bring at-home blood testing to medical weight loss in Finland

Nightingale Health
New partnership for Nightingale in the UK
Analyst Comment18.08.2026 klo 10.18 by
Antti Siltanen

New partnership for Nightingale in the UK

The partnership paves the way in the UK private healthcare market.

Nightingale Health
Press release17.08.2026 klo 11.30

Nightingale Health and Personalised Health Clinics collaborate on preventive metabolic health in the UK

Nightingale Health
Press release01.07.2026 klo 16.00

Nightingale Health and Archipelago Health partner to bring preventive screening to small-island health systems in the Crown Dependencies, Bermuda and the Caribbean

Nightingale Health
Regulatory press release29.06.2026 klo 18.15

Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health
Nightingale: We factored the project delay into our estimates
Research12.06.2026 klo 10.20 by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health
Nightingale's profit warning: Project delay shifts revenue to next year
Analyst Comment09.06.2026 klo 09.40 by
Antti Siltanen

Nightingale's profit warning: Project delay shifts revenue to next year

The company's business appears to be progressing in line with our estimates.

Nightingale Health
Regulatory press release08.06.2026 klo 19.25

Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

Nightingale Health
Nightingale: Nightingale sings to a deaf market
Research04.06.2026 klo 09.36 by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
Nightingale joins wellbeing services county research project
Analyst Comment29.05.2026 klo 09.46 by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release28.05.2026 klo 11.00

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release27.05.2026 klo 16.45

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health
New partnership for Nightingale
Analyst Comment25.05.2026 klo 09.11 by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release22.05.2026 klo 09.30

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release21.05.2026 klo 17.25

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release18.05.2026 klo 13.02

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026 klo 12.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit